SAGE Therapeutics Inc. (SAGE)

180.90
6.50 3.50
NASDAQ : Health Technology
Prev Close 187.41
Open 187.60
Day Low/High 180.00 / 188.49
52 Wk Low/High 79.88 / 193.56
Volume 262.57K
Avg Volume 397.70K
Exchange NASDAQ
Shares Outstanding 51.15M
Market Cap 9.72B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sage Therapeutics To Participate In Goldman Sachs Healthcare Conference

Sage Therapeutics To Participate In Goldman Sachs Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Mood Disorders

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Mood Disorders

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the initiation of Phase 2 clinical...

Allergan, Apple, Oakland Capital: Doug Kass' Views

Allergan, Apple, Oakland Capital: Doug Kass' Views

Doug Kass shares his thoughts on China and life insurers.

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Movement Disorders

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Movement Disorders

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the initiation of Phase 2 clinical...

Facebook, Apple, Starbucks: Doug Kass' Views

Facebook, Apple, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on managing and selecting short-term trades.

Sage Therapeutics To Webcast R&D Day On December 13, 2016

Sage Therapeutics To Webcast R&D Day On December 13, 2016

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will webcast its R&D...

Sage Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for...

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

Sage Therapeutics To Present At American Epilepsy Society 70th Annual Meeting

Sage Therapeutics To Present At American Epilepsy Society 70th Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at...

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Facebook, Home Depot, Disney: Doug Kass' Views

Facebook, Home Depot, Disney: Doug Kass' Views

Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.

SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression

SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the European Medicines...

Allergan, Macy's, Apple: Doug Kass' Views

Allergan, Macy's, Apple: Doug Kass' Views

Doug Kass shares his thoughts on closed-end municipal bond funds.

Sage Therapeutics To Present At Society For Neuroscience 2016 Annual Meeting

Sage Therapeutics To Present At Society For Neuroscience 2016 Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the...

Sage Therapeutics To Present At The Stifel 2016 Healthcare Conference

Sage Therapeutics To Present At The Stifel 2016 Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about Friday's positives and retail's woes.

CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

In the section Expected Near-Term Clinical Milestones, under Trial Initiations, the fourth bullet should read "Sage-217 in MDD" (instead of "Sage-547").

Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting

Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive results on secondary endpoints from...

Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable

Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics To Present At The Neurocritical Care Society 14th Annual Meeting

Sage Therapeutics To Present At The Neurocritical Care Society 14th Annual Meeting

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming poster presentations at the...

Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock

Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public...

'Mad Money' Lightning Round: I Believe in Walt Disney

'Mad Money' Lightning Round: I Believe in Walt Disney

Cramer is a fan of IBM and Tech Data.

Jim Cramer's 'Mad Money' Recap: The Perils of Competition

Jim Cramer's 'Mad Money' Recap: The Perils of Competition

When it comes to stock prices, competition has a lot of influence, Cramer says.

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten...

Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression

Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics

Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the publication of a study conducted...

Short Interest In Sage Therapeutics Expands By 12.7%

Short Interest In Sage Therapeutics Expands By 12.7%

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 463,924 share increase in total short interest for Sage Therapeutics Inc , to 4,131,029, an increase of 12.65% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.